Cutting copper curbs angiogenesis, studies show.
C
C
Vanchieri
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy; D002614:Chelating Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003300:Copper / Q000009:adverse effects* / Q000097:blood / Q000378:metabolism; D005909:Glioblastoma / Q000188:drug therapy; D006801:Humans; D008982:Molybdenum / Q000627:therapeutic use*; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000139:chemically induced / Q000188:drug therapy*; D010396:Penicillamine / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D002614:Chelating Agents; D003300:Copper; D008982:Molybdenum; C020809:tetrathiomolybdate; D010396:Penicillamine